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Abstract
Introduction: Selecting a marginal donor in liver transplantation (LT) remains controversial but is necessary
because of the small number of available donors.
Case presentation: A 46-year-old Japanese woman was a candidate to donate her liver to her brother, who had
decompensated liver cirrhosis of unknown origin. Eight years before the donation, she had a mild liver dysfunction
that was diagnosed as a hepatitis C virus (HCV) infection (serotype 2). She had received anti-viral therapy with
interferon a-2b three times weekly for 24 weeks and had a sustained viral response (SVR). A biopsy of her liver
before the donation showed normal findings without any active hepatitis, and her serum was negative for HCV-
RNA. Only 67 patients have undergone LT from a cadaveric donor in Japan. The family in this case decided to
have living donor LT. A careful selection for the liver graft donation was made; however, since she was the only
candidate, we approved her as a living donor. She was discharged nine days after the liver donation. Her liver
function recovered immediately. A computed tomography scan showed sufficient liver regeneration one year later.
Her brother also had good liver function after LT and had no HCV infection 48 months after surgery and no de
novo malignancy. Neither of the siblings has developed an HCV infection.
Conclusions: A patient with SVR status after interferon therapy might be considered a candidate for living donor
LT but only if there are no other possibilities of LT for the recipient. A careful follow-up of the donor after donation
is needed. The recipient also must have a very close follow-up because it is difficult to predict what might happen
to the graft with post-transplant immunosuppression.
Introduction
The number of deceased donor liver transplantations
(DDLTs) in Japan is extremely small. There were 67
cases between February 1999 and January 2010, accord-
ing to the Japan Organ Transplant Network [1]. There-
fore, living donor liver transplantation (LDLT) is the
most frequent treatment option for patients with end-
stage liver disease in Japan. The main advantage of
LDLT over DDLT is that the donor can be completely
evaluated, before the operation, to exclude many medi-
cal problems. However, the indications for a living
donor should be strict and the risk to the donor must
be avoided with the greatest care. Donors with possibly
morbid liver conditions, including fatty infiltration or a
history of viral hepatitis, and older donors offer “mar-
ginal grafts”, which should be used only after very care-
ful evaluation. A hepatitis B virus (HBV) core antibody
seropositive donor can be accepted as long as HBV sur-
face antigen is seronegative and anti-viral treatment is
administered to the recipient after transplantation [2,3].
In this way, donor safety also is established, according
to several reports of this type of case [4-6]. Some inves-
tigators reported that the patients obtained a sustained
viral response (SVR) after interferon therapy showed
that there was no tendency to develop fibrotic liver in
t h ef u t u r e[ 7 , 8 ] .H C V - R N Aw a sn o td e t e c t e di n8 8 %o f
the serum and liver biopsies of patients with an SVR
[9]. The infection rate of the recipient from an HCV-
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any medium, provided the original work is properly cited.positive graft should be low after LT. The rate of carci-
nogenesis has increased at an annual rate of 0.11% after
an SVR was maintained with anti-viral therapy [10].
Using a graft with a positive hepatitis C virus (HCV)
antibody although HCV-RNA was not detected in the
blood remains controversial in Western countries
[11-13]. To the best of our knowledge, there is no actual
data that shows the outcome of liver transplantation
with a graft from patients who acquire an SVR after
successful anti-viral therapy. Here, we report the case of
a living donor who had an SVR before LDLT. The case
is described and discussed in detail.
Case presentation
A 46-year-old Japanese woman donated the right lobe of
her liver to her 36-year-old brother, who had decom-
pensated cirrhosis of unknown origin. She experienced
mild liver dysfunction (117IU/L in alanine aminotrans-
ferase, normal range of 5 to 30IU/L) eight years before
the donation. Her condition was diagnosed as chronic
active HCV infection (serotype 2) on the basis of a liver
biopsy and viral study that showed that her level of
HCV-RNA was 13 kcopy/mL by real-time polymerase
chain reaction analysis. The histological diagnosis
showed chronic hepatitis A1/F1 (Figure 1). She received
anti-viral therapy with intra-muscular interferon a-2b
three times weekly for 24 weeks. Her serum HCV assay
results were negative after two weeks of effective anti-
viral therapy.
She was doing well and no HCV-RNA had been
detected. She maintained an SVR without any complica-
tions until she was evaluated as a living donor. The
donor evaluation revealed anti-HCV antibody, but her
liver function test results were normal and HCV-RNA
was negative by polymerase chain reaction analysis. She
underwent an ultrasound-guided needle biopsy of her
liver, and the pathological findings were normal and
there were no findings of active hepatitis (Figure 2). She
was approved as a living donor after a thorough evalua-
tion by the ethics committee of the Nagasaki University
Graduate School of Biomedical Sciences. She was dis-
charged nine days after the liver donation. Her liver
function recovered immediately. A computed tomogra-
phy scan one year later showed that she had sufficient
liver regeneration. Her brother was also doing well after
the LT and had no HCV infection 40 months after sur-
gery and no de novo malignancy.
Discussion
Selecting a living donor in this case might be controver-
sial, although a marginal donor can also sometimes be a
candidate. The risks in this case included HCV trans-
mission to the recipient, HCV reactivation in the recipi-
ent after LDLT, and donor risk during surgery. A
number of studies have reported that the results with
recipients of an HCV-infected graft were comparable to
those of recipients of an HCV-negative graft [11-13].
The Scientific Registry of the United Network for Organ
Figure 1 A liver biopsy showed chronic active hepatitis A1/F1 before interferon therapy.
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was significantly higher in the recipients of HCV-posi-
tive grafts than in recipients of HCV-negative grafts
[13]. These results demonstrated that the use of an
HCV-positive graft may also be acceptable in cadaveric
LT. In contrast, an HCV-infected graft was not accepta-
ble in LDLT. Patients who have HCV and who acquire
an SVR after interferon therapy can be considered living
donor candidates.
In this case, it was difficult to determine the indica-
tions for the donor selection before transplantation.
Patients with serotype 2 HCV are more likely to achieve
an SVR after interferon therapy than those with serotype
1. Our donor achieved an SVR of HCV. She and her
brother were fully informed of the risk of peri-operative
complications and the possibility that he would receive
an HCV infection from the graft although she had
obtained an SVR after anti-viral therapy. In theory, it is
unlikely that a recipient would develop a viral infection
from a graft that achieved an SVR.
Conclusions
We report a case of LDLT from a donor previously trea-
ted with interferon for HCV. A patient with SVR status
after interferon therapy might be considered a candidate
for LDLT only if there are no other possibilities of LT
for the recipient. A careful follow-up of the donor after
donation is needed. The recipient also must have a very
close follow-up because it is difficult to predict what
might happen to the graft with post-transplant
immunosuppression.
Consent
Written informed consent was obtained from the patient
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